Searched for
MONOCLONAL ANTIBODY BIOSIMILAR
Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar PebrilzoBiocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, ...- Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
- Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilarAurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...
- Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drugBiocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's...
- Biocon Biologics gets US nod to launch Stelara biosimilarBiocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions...
- Alvotech, Dr. Reddy's ink pact for commercialisation of denosumabAlvotech and Dr. Reddy's partner for AVT03, a biosimilar to Prolia and Xgeva, treating osteoporosis and skeletal-related events. The agreem...
- Biocon Biologics inks licence pact with Janssen for biosimilar productThe agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Bioco...
- Biocon Biologics inks out-licensing agreement with Yoshindo IncUnder the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- develo...
- Cadila Healthcare Q1 results: Net profit rises 29% to Rs 587 crConsolidated total revenue from operations stood at Rs 4,025.4 crore for the quarter under consideration against Rs 3,514.6 crore for the s...
- True North buys into Biocon Biologics, deal values firm at around $3.5 billionTrue North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...
- Biocon, Mylan launch cancer drug in US marketOgivri, available in a 420mg multi-dose vial and a 150mg single-dose vial, will be used for treatment of all types of breast cancer and met...
- FDA okays Glenmark's first-in-human study for respiratory drugAccording to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 bi...
- Torrent Pharma launches Adalimumab biosimilar in IndiaThe company's product will be available as pre-filled syringe of 40 mg, Torrent Pharmaceuticals said in a statement.
- Hetero launches biosimilar Rituximab in IndiaHetero has launched biosimilar Rituximab in India used for treatment of certain types of cancers and rheumatoid arthritis under the brand n...
- NeuClone to collaborate with Serum Institute of India; to supply drugs globallyNeuClone has retained licence to the jointly developed biosimilars for the developed markets of USA, Europe, Canada, Australia, Taiwan.
- Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon"We have focused on creating key growth drivers and have structured the company along those growth drivers," says Kiran Mazumdar Shaw.
- Biocon logs smart recovery in fourth quarterAfter the divestment of Axicorp and the snapping of its biosimilar insulin deal with Pfizer, the company was expected to post a subdued per...
- Biotech drugs to replace chemical entities Lipitor & Plavix as market leadersThe global pecking order of blockbusters may soon be heading for a major upheaval with biotech drugs toppling the present market leaders.
- Rel Life Sciences to focus on R&D, for nowThe company is all set to launch fifth biosimilar drug and seeks approvals for clinical trials and stem-cell treatment.
Load More
